ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Plasma tau biomarkers are distinctly associated with tau tangles and decreased with Lewy body pathology.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Plasma P-tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- Post mortem MRI of cholinergic white matter pathways across neurodegenerative diseases.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- CSF and plasma tau biomarkers in the Down syndrome-Alzheimer's disease continuum.EBioMedicine · 2026Article
- Plasma phosphorylated tau 217 detects amyloid-β in neuronal synuclein disease.NPJ Parkinson's disease · 2026Article
- Analytical and clinical validation of the Lumipulse G plasma p-tau217 assay for clinical implementation.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Plasma pTau217 as a Prognostic, Monitoring, and Risk-Stratification Biomarker of Clinical Progression in Lewy Body Disease.medRxiv : the preprint server for health sciences · 2026Article
- Plasma biomarkers of Alzheimer's disease and their association with disproportionately enlarged subarachnoid space hydrocephalus.Fluids and barriers of the CNS · 2026Article
- Plasma tau biomarkers are distinctly associated with tau tangles and decreased with Lewy body pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
introductionPlasma-to-autopsy studies are essential to understand how tau blood biomarkers change in relation to Alzheimer's disease (AD) brain pathology and how they are influenced by brain co-pathologies and comorbidities.
methodsPlasma samples from 102 brain donors of the Vallecas Alzheimer Reina Sofia cohort were analyzed using a mass spectrometry method to measure the levels of six phosphorylated and two non-phosphorylated tau biomarkers.
resultsIn cases with high pathological burden of AD, phosphorylated tau (p-tau)217 showed associations with neurofibrillary tangle counts across all regions, while p-tau205 was primarily linked to the frontal cortex, and the non-phosphorylated tau peptides were linked to the temporal cortex. Plasma tau levels decreased as Lewy body pathology progressed, even among individuals at the same tau Braak stage. All plasma biomarkers correlated with creatinine levels, as a marker of renal dysfunction, but this effect was mitigated when using the ratios phospho/non-phospho. DISCUSSION: Understanding how plasma tau biomarkers are influenced by co-pathologies and comorbidities is crucial for their accurate implementation. HIGHLIGHTS: The plasma phosphorylated tau (p-tau)217 ratio, followed by the p-tau205 ratio and p-tau217, were the best-performing biomarkers for detecting neuropathologically confirmed Alzheimer's disease (AD). In high AD cases, p-tau217 showed associations with neurofibrillary tangle (NFT) counts across all regions, while p-tau205 was primarily linked to the frontal cortex, and non-phosphorylated tau peptides were linked to the temporal cortex. We observed a decline in plasma tau levels as Lewy body pathology progressed, even among individuals at the same tau Braak stage. All plasma biomarkers correlated with creatinine levels, as a marker of renal dysfunction, but this effect was mitigated when using the ratios. Plasma p-tau199 displayed a distinct behavior compared to other p-tau species, showing no association with NFT counts in any brain region, but demonstrating significant correlations with brain volume and an effect on survival time.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.